AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02062853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Group
Description: Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
Study NCT02062853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Group
Description: The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
Study NCT03049033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic Music Therapy
Description: Neurologic Music Therapy uses rhythms to change brain activity and function.
Study NCT03049033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Occupational Therapy uses traditional motor training.
Study NCT03049033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Supported Therapy
Description: Music Supported Therapy uses musical instruments to train fine motor movements.
Study NCT02456311 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HARMONIC ACE+7
Description: Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
Study NCT05054634 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psycho-oncological Intervention Based on Counselling (PIBC)
Description: Patients in EG received a psycho-oncological intervention based on Counselling (PIBC) following the scheme proposed by Arranz and Cancio in addition to the standard treatment. The evolution of anxiety and depression was evaluated using Hospital Anxiety and Depression Scale (HADS). The aim of the study was to evaluate the effectiveness of a PIBC in reducing anxiety and depression of patients with DTC. Other QoL relevant items were also evaluated using the Short Form-36 Health Survey (SF-36) and Psychological General Well-Being Index (PGWBI) scales.
Study NCT00510237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)
Description: The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
Study NCT03638973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
Study NCT03638973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
Study NCT01557114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy
Study NCT01557114 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
Study NCT04737187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/Tipiracil
Description: Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
Study NCT04737187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
Study NCT04737187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: administered every 2 weeks (Day 1 and Day 15)
Study NCT02280694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT02280694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02280694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT02280694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT02865226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)
Study NCT02865226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).
Study NCT02166112 — intervention group
Intervention type: PROCEDURE
Intervention: Permacol mesh placement
Description: All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
Study NCT00963053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VA111913 TS and placebo
Description: VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
Study NCT00963053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA111913 TS and placebo
Description: VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
Study NCT03183726 — intervention group
Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-DFU
Description: ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention.
Study NCT03707002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: scFOS
Description: daily intake for 6 weeks
Study NCT03707002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: daily intake for 6 weeks
Study NCT00026130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
Study NCT00026130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
Study NCT00026130 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
Study NCT02097940 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proprioceptive exercises
Description: Exercises with movements, jumping and imbalance.
Study NCT05222867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower back massage
Description: Lower back massage performance: In the study, Linda Kimber's massage protocol was used. First, the researcher ensured that the patient was holding the bed, squatting, or bent over on the bed, which is suitable for the massage, between two contractions. The pregnant woman was instructed to breathe deeply and exhale audibly when her contractions began. Gloves were worn during the massage and liquid Vaseline, which does not contain any active substance, was used to provide lubricity. The circular hip massage was applied at the beginning of the contraction, and lower lateral area and sacral pressure massage was applied towards the end of the contraction as per the massage protocol, and simultaneously with the inhaling sound of the pregnant woman
Study NCT04096690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment
Study NCT04096690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
Study NCT00372645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid (supplement)
Description: 200 µg folate per day from supplemental folic acid
Study NCT00372645 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Metafolin (supplement)
Description: 200 µg folate per day from supplemental Metafolin®
Study NCT00372645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04183101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.
Study NCT04183101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.
Study NCT00372645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Folate rich foods
Description: 200 µg folate per day from folate-rich foods
Study NCT06071559 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Roux-en-y gastric bypass
Description: Obesity surgery
Study NCT01279213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paliperidone clozapine
Description: dose 3 to 12 mg paliperidone ER daily during 12 weeks
Study NCT01080261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element
Description: PROMUS Element Everolimus-Eluting Coronary Stent System
Study NCT01279213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paliperidone clozapine
Description: dose 3 to 12 mg paliperidone ER daily during 12 weeks
Study NCT01459900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal artery ablation
Description: Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
Study NCT01459900 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal angiography
Description: Renal angiography by femoral access.
Study NCT00350233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Study NCT01910181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
Study NCT04141605 — intervention group
Intervention type: DEVICE
Intervention: SherpaPak Cardiac Transport System
Description: The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.
Study NCT03409627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INXN-4001
Description: Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
Study NCT00744341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 1.25mg i.v. bid
Study NCT00744341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 3.75mg i.v. bid
Study NCT00744341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 7.5mg i.v. bid
Study NCT00744341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV320
Description: 15.0mg i.v. bid
Study NCT03319849 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NT-501
Description: Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional.
Study NCT03319849 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
Study NCT00744341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01922999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: patients will receive placebo, 1mg melatonin or 3mg melatonin
Study NCT01865851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Face Mask and NuMask
Study NCT01715246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Study NCT01715246 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infant Formula
Study NCT01125930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
Study NCT01125930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atralin gel
Description: Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
Study NCT03627676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
Study NCT05105685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone
Description: RhGH treatment was started at 0.1 IU/kg once daily
Study NCT05105685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline was started at 0.1 IU/kg once daily as the placebo
Study NCT03981861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Spironolactone
Description: Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
Study NCT06611189 — intervention group
Intervention type: OTHER
Intervention: surgery
Description: In order to preserve kidney from warm ischemia during graft implantation, on the back table, graft were prepared for implantation with standard techniques. The kidney was introduced into the bag which was filled with a small amount of ice and preservation fluid (Figure 1). After inplacement of the graft, a small hole was made near the hilum and the renal artery and vein were passed through the hole. A Kocher clamp was used to maintain the fluid and ice in place and as a handle. Also, a Hartman Mosquito Clamp was used to mark urether-side, and to maintain orientation.
Study NCT06611189 — intervention group
Intervention type: OTHER
Intervention: Ray-Tech sponge technique
Description: On the back table, graft were prepared for implantation with standard techniques. A Raytech sponge is soaked in ice-cold preservative solution, and wrapped around the kidney and held with a clamp (Figure 2). Position and oriantation of the graft was done by direct vision of urether.
Study NCT01307579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin Acetate
Description: Given IV
Study NCT01307579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Given IV or PO
Study NCT01307579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01307579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02871258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The MetaNeb® System
Study NCT02934685 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofraction
Description: 70 Gy in 28 fractions over 5.6 weeks
Study NCT02934685 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: convention
Description: 80Gy in 40 fractions over 8 weeks
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mL Colloid Preload
Description: 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
Study NCT02961842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
Study NCT02961842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 µg will be administered in the subarachnoid space
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 µg will be administered in the subarachnoid space
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mL Crystalloid Coload
Description: Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
Study NCT02961842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 mL Crystalloid Coload
Description: Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
Study NCT02961842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision
Study NCT02961842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision
Study NCT02961842 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Assessment of the Inferior Vena Cava
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
Study NCT02961842 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound Assessment of the Inferior Vena Cava
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region